STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens ...

Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current ...

Continued progress on the buyout of Bausch & Lomb is lifting shares, with the stock up over 6% at the time of writing. Financial Times reported on Oct. 14 that two prominent figures involved in ...

VAUGHAN, Ontario (AP) — VAUGHAN, Ontario (AP) — Bausch + Lomb Corporation (BLCO) on Wednesday reported third-quarter net income of $4 million, after reporting a loss in the same period a year earlier.

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.